Perspective Therapeutics Management
Management criteria checks 0/4
Perspective Therapeutics' CEO is Thijs Spoor, appointed in Feb 2023, has a tenure of 2.25 years. total yearly compensation is $5.37M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $196.41K. The average tenure of the management team and the board of directors is 1.8 years and 2.3 years respectively.
Key information
Thijs Spoor
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 11.5% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$5m | US$619k | -US$78m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$52m |
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$1m | US$506k | -US$37m |
Compensation vs Market: Thijs's total compensation ($USD5.37M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Thijs's compensation has increased whilst the company is unprofitable.
CEO
Thijs Spoor (52 yo)
2.3yrs
Tenure
US$5,371,889
Compensation
Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$5.37m | 0.12% $ 196.4k | |
| Chief Accounting Officer | less than a year | US$1.50m | 0.066% $ 109.3k | |
| Chief Medical Officer | 2.3yrs | US$2.03m | 0.19% $ 308.1k | |
| Chief Financial Officer | less than a year | no data | 0.048% $ 79.2k | |
| Executive Vice President of Operations | 1.8yrs | no data | no data | |
| Chief Science Officer | no data | no data | 2% $ 3.3m | |
| Vice President of Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | no data | no data | no data | |
| Executive Vice President of Brachytherapy | 2.1yrs | no data | no data | |
| Chief Business Strategy Officer | no data | no data | no data | |
| Senior Vice President of Clinical Operations | no data | no data | no data | |
| Senior Vice President of Clinical Development | 1.3yrs | no data | no data |
1.8yrs
Average Tenure
52yo
Average Age
Experienced Management: CATX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$5.37m | 0.12% $ 196.4k | |
| Independent Director | 2.3yrs | US$267.54k | 0.15% $ 244.9k | |
| Independent Director | 2.3yrs | US$267.54k | no data | |
| Independent Director | 1.9yrs | US$267.54k | 0.035% $ 58.2k | |
| Chairperson of the Board | 6.9yrs | US$282.54k | 0.25% $ 421.7k |
2.3yrs
Average Tenure
58yo
Average Age
Experienced Board: CATX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 11:27 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perspective Therapeutics, Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Alec Stranahan | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |